23 drugs in the Neurology & psychiatry family lose patent protection between 2026 and 2031. The family comes from the WHO ATC classification of each drug's ingredient; it is a filter, not a claim about any drug's approved indication.
This is the earliest date a generic could enter; it is not a guarantee one will. We calculate it as the later of the last patent the company listed with the FDA and the last regulatory exclusivity. Companies often reach settlement agreements with generic makers for a different date, and those agreements are not public in this data.
Nuedexta (dextromethorphan hydrobromide; quinidine)Otsuka America Pharmaceutical · 1 patent · August 13, 2026
Aricept (donepezil hydrochloride)Eisai · 1 patent · October 4, 2026
Naropin (ropivacaine hydrochloride)Fresenius Kabi USA · 2 patents · November 28, 2026
Vyndaqel (tafamidis meglumine)Foldrx Pharmaceuticals LLC A Wholl · 2 patents · December 19, 2026
Dates from the FDA Orange Book, the official record of which patents cover
which approved drug; updated monthly. Facts only, not investment advice. Verify against the
Orange Book and primary filings. pdufa.bio is not affiliated with the FDA.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.